Moderna (NASDAQ: MRNA) was the top-performing stock in the S&P 500 not too long ago when the company joined the index in mid-2021. At its peak in 2021, the company's value soared to $187 billion ...

Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...

Moderna (MRNA 1.95%) has lost more than half of its value this year. The bullish investors have largely left, and the stock has plunged to levels it hasn't seen in years. Rival Pfizer has also ...

Moderna (MRNA) closed at $58.39 in the latest trading session, marking a -0.56% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 0.97%. Elsewhere, the Dow ...

This stock used to be a highflyer but has struggled in recent years as demand waned for its flagship product. Though Moderna ...

Overall, the performance of MRNA stock with respect to the index has been quite volatile. Returns for the stock were 143% in 2021, -29% in 2022, and -45% in 2023.

Moderna Inc. entered the new year on the heels of a worsening stock performance in 2024. The Cambridge drugmaker’s stock dropped even further after lowering its expected revenue range for 2025 ...

Why Moderna stock fell. Moderna's bizarre stock price performance during the week ending May 31 had two main factors. First, enthusiasm for the vaccine developer's artificial intelligence ...

We expect the Covid-19 shot to remain the primary driver of Moderna’s performance in 2022 as well. The global inoculation drive is still in the early stages, with the Bloomberg Vaccine Tracker ...